CN110021437B - Diabetes management method and system - Google Patents
Diabetes management method and system Download PDFInfo
- Publication number
- CN110021437B CN110021437B CN201711047697.8A CN201711047697A CN110021437B CN 110021437 B CN110021437 B CN 110021437B CN 201711047697 A CN201711047697 A CN 201711047697A CN 110021437 B CN110021437 B CN 110021437B
- Authority
- CN
- China
- Prior art keywords
- user
- diabetes
- value
- management
- inspection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 59
- 238000007726 management method Methods 0.000 title abstract description 61
- 238000007689 inspection Methods 0.000 claims abstract description 66
- 238000011156 evaluation Methods 0.000 claims abstract description 56
- 230000000694 effects Effects 0.000 claims abstract description 46
- 238000004393 prognosis Methods 0.000 claims abstract description 31
- 238000012544 monitoring process Methods 0.000 claims abstract description 28
- 239000008280 blood Substances 0.000 claims description 85
- 210000004369 blood Anatomy 0.000 claims description 85
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 52
- 239000008103 glucose Substances 0.000 claims description 52
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 19
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims description 19
- 235000005911 diet Nutrition 0.000 claims description 11
- 230000037213 diet Effects 0.000 claims description 11
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 10
- 238000012502 risk assessment Methods 0.000 claims description 9
- 238000004364 calculation method Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 12
- 238000012216 screening Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 2
- 208000017667 Chronic Disease Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000037149 energy metabolism Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000014770 Foot disease Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Data Mining & Analysis (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Biomedical Technology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
The invention discloses a method and a system for managing diabetes mellitus, and relates to the technical field of medical assistance. The management method comprises the following steps: receiving corresponding inspection parameters according to the working mode selected by the user; comparing and analyzing the inspection parameters with preset standards to obtain an evaluation result; and providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the evaluation result. According to the invention, the risk, the curative effect, the prognosis and the like of the illness are evaluated according to the checking result input by the user, corresponding monitoring plans and daily management suggestions are given, and specialized whole-course guidance and self-management are provided. Can better realize the screening and early intervention prevention of the diabetes high risk group, guide the treatment scheme and the early intervention and treatment of the diseases.
Description
Technical Field
The invention relates to the technical field of medical assistance, in particular to a method and a system for managing diabetes.
Background
Diabetes is a metabolic disease characterized by hyperglycemia, and belongs to chronic diseases. The chronic disease management refers to medical behaviors and processes of periodically detecting, continuously monitoring, evaluating and comprehensively intervening and managing chronic non-infectious diseases and risk factors thereof, and mainly includes early screening of chronic diseases, prediction of chronic disease risks, early warning and comprehensively intervening, comprehensive management of chronic disease groups, evaluation of chronic disease management effects and the like. In fact, chronic disease management is the management of chronic patients and high risk groups, including the management and intervention of the reasonable diet, behavior habit, health and psychological aspects of the chronic patients; propaganda of correct slow disease management concept, knowledge and skill, and realization of comprehensive slow disease prevention and treatment work.
At present, the chronic disease management is mainly carried out by medical and health institutions, and countries with developed medical services build a chronic disease management system through community services, however, the countries do not have the conditions, and patients or high-risk groups only need to visit hospitals for a limited number of times to know the conditions of the patients, so that the problems cannot be found timely. Along with the fact that the portable inspection equipment goes deep into the life of people, people can grasp the situation of the people through self-inspection, and scientific chronic disease management suggestions can be obtained by matching with a corresponding management system.
Disclosure of Invention
The invention aims to provide a diabetes management method and a diabetes management system, which can provide an individualized chronic disease monitoring plan and a management scheme according to the daily examination result of a user and help the user to effectively manage the chronic disease.
To achieve the purpose, the invention adopts the following technical scheme:
In one aspect, the present invention provides a method for managing diabetes, comprising:
Receiving corresponding inspection parameters according to the working mode selected by the user;
Comparing and analyzing the inspection parameters with preset standards to obtain an evaluation result;
and providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the evaluation result.
Wherein, according to the working mode selected by the user, receiving the corresponding checking parameters comprises:
If the working mode is risk assessment, the examination parameters are fasting blood glucose value and blood triglyceride value, or sugar load 2h blood glucose value and blood triglyceride value;
Correspondingly, comparing and analyzing the inspection parameters with preset standards to obtain an evaluation result, which comprises the following steps:
and judging the threshold range to which the inspection parameters belong, and obtaining the risk level of the user suffering from diabetes.
Wherein, according to the working mode selected by the user, receiving the corresponding checking parameters comprises:
If the working mode is efficacy evaluation, the examination parameters comprise glycosylated hemoglobin value and fasting blood glucose value;
Correspondingly, comparing and analyzing the inspection parameters with preset standards to obtain an evaluation result, which comprises the following steps:
Calculating variation coefficients of fasting blood sugar in a period, judging threshold ranges of the inspection parameters and the variation coefficients of the fasting blood sugar, or judging variation conditions of the inspection parameters and the variation coefficients of the fasting blood sugar before and after treatment, and obtaining the curative effect grade of taking medicine by a user.
Further, if the working mode is efficacy evaluation, the examination parameters further include blood triglyceride values;
Correspondingly, comparing and analyzing the inspection parameters with preset standards to obtain an evaluation result, which comprises the following steps:
Calculating variation coefficients of fasting blood sugar in a period, judging threshold ranges of the inspection parameters and the variation coefficients of the fasting blood sugar, or judging variation conditions of the inspection parameters and the variation coefficients of the fasting blood sugar before and after treatment, and obtaining the curative effect grade of taking medicine by a user.
Wherein, according to the working mode selected by the user, receiving the corresponding checking parameters comprises:
if the working mode is prognosis evaluation, checking parameters including glycosylated hemoglobin value and/or total cholesterol value;
receiving the condition of whether complications exist or not input by a user;
Correspondingly, comparing and analyzing the inspection parameters with preset standards to obtain an evaluation result, which comprises the following steps:
Judging the threshold range of the inspection parameter to obtain the prognosis effect grade of the user;
Correspondingly, according to the evaluation result, a monitoring plan and a management scheme of the diabetes inspection parameters are provided, comprising:
And providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the prognosis effect grade and the condition of the complications.
As a preferred embodiment, before providing a monitoring plan and management scheme for diabetes inspection parameters according to the evaluation result, the method further comprises:
Acquiring basic information of a user, including gender, age, height, weight, occupation, daily activity level and diet condition;
Correspondingly, according to the evaluation result, a monitoring plan and a management scheme of the diabetes inspection parameters are provided, comprising:
and calculating calories consumed and ingested by the user according to the basic information, and providing a monitoring plan of the diabetes inspection parameters and a management scheme of daily life for the user by combining the evaluation result and the calculation result.
In another aspect, the present invention provides a diabetes management system, comprising:
the user interaction module is used for receiving corresponding checking parameters according to the working mode selected by the user;
the evaluation module is used for comparing and analyzing the inspection parameters with preset standards to obtain an evaluation result;
and the advice output module is used for providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the evaluation result.
The user interaction module is specifically configured to:
If the working mode is risk assessment, the examination parameters are fasting blood glucose value and blood triglyceride value, or sugar load 2h blood glucose value and blood triglyceride value;
correspondingly, the evaluation module is specifically configured to:
and judging the threshold range to which the inspection parameters belong, and obtaining the risk level of the user suffering from diabetes.
The user interaction module is specifically configured to:
If the working mode is efficacy evaluation, the examination parameters comprise glycosylated hemoglobin value, fasting blood glucose value and blood triglyceride value;
correspondingly, the evaluation module is specifically configured to:
Calculating variation coefficients of fasting blood sugar in a period, judging threshold ranges of the inspection parameters and the variation coefficients of the fasting blood sugar, or judging variation conditions of the inspection parameters and the variation coefficients of the fasting blood sugar before and after treatment, and obtaining the curative effect grade of taking medicine by a user.
The user interaction module is specifically configured to:
If the working mode is prognosis evaluation, checking parameters including glycosylated hemoglobin value and/or total cholesterol value; receiving the condition of whether complications exist or not input by a user;
correspondingly, the evaluation module is specifically configured to:
Judging the threshold range of the inspection parameter to obtain the prognosis effect grade of the user;
correspondingly, the suggestion output module is specifically configured to:
And providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the prognosis effect grade and the condition of the complications.
Further, the management system further includes: a basic information acquisition module for providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the evaluation result,
Acquiring basic information of a user, including gender, age, height, weight, occupation, daily activity level and diet condition;
correspondingly, the suggestion output module is specifically configured to:
and calculating calories consumed and ingested by the user according to the basic information, and providing a monitoring plan of the diabetes inspection parameters and a management scheme of daily life for the user by combining the evaluation result and the calculation result.
The beneficial effects of the invention are as follows:
And (3) carrying out disease risk, curative effect, prognosis and other evaluations according to the checking result input by the user, giving out corresponding monitoring plans and daily management suggestions, and providing specialized whole-course guidance and self-management. Can better realize the screening and early intervention prevention of the diabetes high risk group, guide the treatment scheme and the early intervention and treatment of the diseases.
Drawings
FIG. 1 is a flowchart of a method for managing diabetes according to an embodiment of the present invention;
Fig. 2 is a schematic structural diagram of a diabetes management system according to a second embodiment of the present invention.
Detailed Description
In order to make the technical problems solved by the present invention, the technical solutions adopted and the technical effects achieved more clear, the technical solutions of the embodiments of the present invention will be described in further detail below with reference to the accompanying drawings, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments.
Example 1
The embodiment provides a diabetes management method, which is suitable for the whole course tracking and management of diabetes patients and high risk groups, and is suitable for various application scenes. The method is executed by a diabetes management system, the system is composed of software and/or hardware, is generally integrated in an intelligent terminal or inspection equipment, has the characteristic of product integration, integrates detection, acquisition, transmission, analysis and storage of data, and can provide specialized management and personalized guidance for diabetics and high-risk groups.
Fig. 1 is a flowchart of a method for managing diabetes according to an embodiment of the invention. As shown in fig. 1, the management method includes the steps of:
s11, corresponding checking parameters are received according to the working mode selected by the user.
The modes of operation include risk assessment, efficacy assessment and prognosis assessment.
If the working mode is risk assessment, the examination parameters comprise one or both of fasting blood glucose values and glucose load 2h blood glucose values, and further comprise blood triglyceride values; if the mode of operation is efficacy assessment, the examination parameters include a glycosylated hemoglobin value and a fasting blood glucose value, as a more preferred embodiment, the examination parameters further include a blood triglyceride value; if the mode of operation is prognostic, the examination parameters include glycosylated hemoglobin values and/or total cholesterol values, and the user is free to choose whether or not to fill in the complication.
The above inspection parameters can be inspected by relevant instruments of a hospital, and can also be self-inspected by a user through portable equipment. The inspection report may be entered manually by a user, or may be imported by a data line interface or a network interface.
S12, comparing and analyzing the inspection parameters with preset standards to obtain an evaluation result.
If the working mode is risk assessment, judging a threshold range to which the corresponding inspection parameter belongs, and obtaining the risk level of the user suffering from diabetes. The fasting blood glucose level, the blood glucose level of the sugar load for 2 hours and the blood triglyceride level are different, the risks of illness of the representative users are also different, and the risk levels comprise low, medium, high and extremely high, so that the screening of the high-risk diabetes people can be realized.
The correspondence between the threshold range of the inspection parameter and the risk level is exemplified below. When the fasting blood glucose value is less than 5.0mmol/L and the blood triglyceride value is less than 2.3mmol/L, the risk of low is judged; when the fasting blood glucose value is between 5.6 and 6.1mmol/L and the triglyceride value in blood is less than 2.3mmol/L, the risk is judged to be moderate; a high risk can be determined when the fasting blood glucose value is between 6.1 and 7.0mmol/L and the blood triglyceride value is <2.3 mmol/L; when the fasting blood glucose value is between 6.1 and 7.0mmol/L and the triglyceride value in blood is more than or equal to 2.3mmol/L, the risk can be judged to be extremely high.
If the working mode is efficacy evaluation, calculating fasting blood glucose data recorded in a statistical period, calculating a variation coefficient of fasting blood glucose, and judging by combining with a threshold range described by other inspection parameters to obtain efficacy grade of executing a treatment scheme by a user. If the examination data of the periodic treatment is only available, judging which threshold range the examination data is in, and if the examination data of the periodic treatment is available, judging the threshold range to which the variation of the examination data belongs. The treatment level includes remarkable treatment effect, obvious treatment effect, general treatment effect, no obvious effect and poor treatment effect.
Firstly, judging the degree of illness state according to recorded inspection data, comprising: mild disease, general disease and serious disease. Wherein the lighter condition means: the new diagnosis of diabetes has short disease course or no complications in the young of <65 years old and no intervention of hypoglycemic drugs or no side effects of hypoglycemic treatment, weight gain and the like. The disease condition generally refers to: most non-pregnant adult patients, the oral hypoglycemic agent of <65 years old, cannot reach the standard and be used or modified with insulin treatment; patients with no risk of hypoglycemia at 65 years or more with a good expected lifetime of the viscera of more than 15 years. Serious disease refers to: the diabetes has longer disease course, has serious history of hypoglycemia, has limited life expectancy, has advanced microvascular or macrovascular complications and has a plurality of complications, and is difficult to reach standard after treatment. The extent of the disease is different, and the applicable threshold ranges are also different.
The correspondence between the threshold range of the examination parameter and the efficacy level is exemplified below. If the illness state of the user is lighter and only has one period of treatment check data, the glycosylated hemoglobin value is less than 6.5 percent, and the fasting blood glucose variation coefficient CV value is less than 0.29, the treatment effect is judged to be obvious. If the illness state of the user is lighter, and two groups of comparison examination data are provided before and after treatment, the glycosylated hemoglobin value after treatment is less than 6.5 percent (or the reduction rate of the glycosylated hemoglobin value before and after treatment is more than or equal to 30 percent), and the fasting blood glucose variation coefficient CV value before treatment is larger than the fasting blood glucose variation coefficient CV value after treatment, the treatment effect can be judged to be remarkable.
If the working mode is prognosis evaluation, respectively judging the threshold range to which the corresponding inspection parameter belongs according to the presence or absence of complications, and obtaining the prognosis effect grade of the user. The prognostic efficacy classes include better, general, worse and worse.
The correspondence of the threshold range of the inspection parameter to the prognostic effect level is exemplified below. When the glycosylated hemoglobin value is less than 7% and the total cholesterol value is between 3.0 and 5.2mmol/L, the prognosis effect is better; when the glycosylated hemoglobin value is <7% and the total cholesterol value is >5.2mmol/L, the prognosis effect is general; when the glycosylated hemoglobin value is 7-8% and the total cholesterol value is more than 5.2mmol/L, the prognosis effect is poor; when the glycosylated hemoglobin value is more than 8% and the total cholesterol is more than 5.2mmol/L, the prognosis effect is poor; and when no complications exist, adjusting a prognosis scheme according to specific conditions to guide a user to prevent the occurrence and development of the complications.
And S13, providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the evaluation result.
In the risk assessment, different management suggestions are provided for the user aiming at different risk levels. The users are required to keep good living habits at low and moderate risks, pay attention to adjusting the diet structure, and strengthen exercise; the high and extremely high risk indicates abnormal indexes, the user is recommended to review timely and periodically, the intervention treatment of life style is enhanced, reasonable diet and work and rest planning is provided for the user to refer to, if the intervention effect is poor, the user is recommended to seek medical attention in time, and the medicine intervention treatment can be selected.
Diabetes is a group of metabolic syndromes characterized by long-term hyperglycemia due to insulin deficiency and/or insulin resistance, and the most important central basis for the high-risk group of diabetes is abnormal glucose regulation and abnormal energy metabolism. When insulin deficiency and/or insulin resistance occurs, glucose is not able to enter the tissue cells effectively, and the availability of glucose is reduced, resulting in an increase in blood glucose levels. The degradation and utilization of glucose further results in a decrease in energy production, and when the energy supply is insufficient, the human body needs to invoke the fat replenishment energy supply through the corresponding energy metabolism regulation mechanism, so that the concentration of the fatty acid is increased, and the triglyceride is the most main energy supply and storage substance, and therefore, the triglyceride level in blood is increased. When the blood sugar and triglyceride levels are in a double high state, the abnormal sugar metabolism and energy metabolism are indicated, and the high risk of diabetes is indicated; and when there is only a single index rise, it is often susceptible to other factors such as: only when the blood glucose level is increased, the blood glucose level may be temporarily increased due to the influence of emotion, diet and the like; only when the triglyceride level is elevated, it may be caused by bad living habits, hyperlipidemia, or the like. Therefore, the prior art only evaluates the risk of developing diabetes with respect to blood glucose levels with insufficient accuracy. In the embodiment, the blood glucose level of fasting blood glucose or the blood glucose level of sugar load for 2 hours is combined with the triglyceride level to judge whether the blood glucose level is in a double high state or not, so that the influence of other interference factors can be effectively eliminated, and the disease risk degree is more accurately estimated. Thus, early intervention is carried out, scientific life style intervention and the like are carried out on high-risk people, and diabetes mellitus can be effectively prevented or delayed.
When evaluating the curative effect, if the curative effect is obvious or effective, the user is recommended to take medicine according to the original plan, and good life and eating habits are kept; if the medicine is invalid, the user is recommended to review, and the medicine is adjusted according to the recommendation of the doctor.
The glycosylated hemoglobin value reflects the average blood glucose level with a period of 2-3 months, and cannot directly reflect the blood glucose excursion. Many studies have shown that blood glucose fluctuations can trigger different metabolic pathways leading to microvascular and macrovascular lesions. The fasting blood glucose variation coefficient (FPG-CV) is the ratio of standard deviation to mean, and can eliminate the influence of different average levels on the variation degree comparison and reflect the fluctuation condition of the daytime blood glucose. By comprehensively considering the information of blood glucose fluctuation and HbA1c, the control condition of blood glucose can be more comprehensively understood. An increase in blood glucose levels, which means a decrease in glucose availability, insufficient energy in the tissues, and the need for the body to invoke fat to supply energy, results in an increase in blood triglyceride levels. Therefore, the lipid metabolism and the energy metabolism can be reflected by the value of triglyceride in blood. By combining the three, whether the sugar metabolism is normal or not can be judged, and meanwhile, whether the sugar metabolism is abnormal or not accompanied with lipid metabolism and energy metabolism can be judged. Therefore, the treatment effect of diabetes can be deeply and comprehensively evaluated, and the method is more beneficial to assisting clinical decision and guiding medication.
In the prognosis evaluation, a monitoring plan and a management scheme of the diabetes inspection parameters are provided according to the prognosis effect grade and the condition of the presence or absence of complications. The prognosis effect grade is better or general, and the user is recommended to control the illness state according to the original plan, review regularly, pay attention to diet and the like; if the prognosis effect grade is poor or bad, the user is guided to visit or change the prognosis scheme according to the corresponding complications with complications; and the prognosis scheme is adjusted according to specific conditions, so that the user is guided to prevent the occurrence and development of complications.
For diabetics, the control of blood glucose is central to determining their prognosis. Optimizing blood sugar control can fundamentally reduce the risk of complications or delay the progress of the complications. And the long-term glucose metabolism disorder can lead to chronic hyperglycemia, cause chronic inflammation, endothelial cell injury, hypercoagulability, microcirculation disturbance and the like, and lead to dysfunction of various tissues and organs. The pathological basis of the diabetic complications is vascular atherosclerosis lesions of corresponding organs, kidney, eye and foot diseases are mainly micro blood vessels, brain and heart diseases are mainly medium blood vessels, but the pathological basis is atherosclerosis, and the direct cause of the arteriosclerosis is the blood fat. Glycosylated hemoglobin is a gold index for evaluating blood sugar control condition, and total cholesterol is an index for reflecting vascular pathological condition, and the combination of the two indexes can accurately predict and judge the occurrence and development of diabetes and complications, and is also beneficial to early discovery or treatment of diabetes complications.
Further, before providing a monitoring plan and a management scheme for blood sugar according to the evaluation result, the method further comprises: acquiring basic information of a user, including gender, age, height, weight, occupation, daily activity level and diet condition; correspondingly, according to the evaluation result and the basic information, a more reasonable monitoring plan and management scheme of the diabetes inspection parameters are customized for the user.
Specifically, the daily intake of calories required by the user is calculated according to the sex, age, height, weight, occupation and daily activity level of the user, and scientific lifestyle intervention is performed through whole course guidance in aspects of diet, exercise and the like. And (3) according to the staged evaluation result, making corresponding adjustment, and making an individual monitoring and management scheme for the user.
The beneficial effects of this embodiment lie in: 1) The method is independent of doctors and big data, so that more accurate judgment is realized; 2) A plurality of specific combinations are carried out on a plurality of diabetes core index parameters, so that the evaluation result is more comprehensive and accurate; 3) The risk assessment, the curative effect assessment and the prognosis assessment are integrated, and different people can be managed in a targeted manner; 4) The data recording, storage and analysis of the diabetes related inspection parameters can be realized; 5) Providing more specialized guiding advice and management for diabetics in the daily self-management process.
Example two
The invention provides a diabetes management system for executing the management method of the embodiment, solving the same technical problems and achieving the same technical effects. The management system is typically integrated within the intelligent terminal or the verification device.
Fig. 2 is a schematic structural diagram of a diabetes management system according to a second embodiment of the present invention. As shown in fig. 2, the management system includes:
The user interaction module 21 is configured to receive the corresponding inspection parameters according to the operation mode selected by the user.
And the evaluation module 22 is used for comparing and analyzing the inspection parameters with preset standards to obtain an evaluation result.
And the advice output module 23 is used for providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the evaluation result.
First, the user interaction module 21 is specifically configured to:
If the working mode is risk assessment, the examination parameters are fasting blood glucose value and blood triglyceride value, or sugar load 2h blood glucose value and blood triglyceride value;
accordingly, the evaluation module 22 is specifically configured to:
and judging the threshold range to which the inspection parameters belong, and obtaining the risk level of the user suffering from diabetes.
Secondly, the user interaction module 21 is specifically configured to:
If the working mode is efficacy evaluation, the examination parameters comprise glycosylated hemoglobin value, fasting blood glucose value and blood triglyceride value;
accordingly, the evaluation module 22 is specifically configured to:
Calculating variation coefficients of fasting blood glucose in a period, judging threshold ranges of the inspection parameters and the variation coefficients of the fasting blood glucose, or judging variation conditions of two adjacent groups of inspection parameters and the variation coefficients of the fasting blood glucose, and obtaining curative effect grades of executing a treatment scheme by a user.
Third, the user interaction module 21 is specifically configured to:
If the working mode is prognosis evaluation, checking parameters including glycosylated hemoglobin value and/or total cholesterol value; and receiving the condition of the complication input by the user.
Accordingly, the evaluation module 22 is specifically configured to:
and judging the threshold range to which the inspection parameter belongs, and obtaining the prognosis effect grade of the user.
Accordingly, the advice output module 23 is specifically configured to:
And providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the prognosis effect grade and the condition of the complications.
Further, the management system further includes: a basic information acquisition module 24 for providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the evaluation result,
Acquiring basic information of a user, including gender, age, height, weight, occupation, daily activity level and diet condition;
accordingly, the advice output module 23 is specifically configured to:
and calculating calories consumed and ingested by the user according to the basic information, and providing a monitoring plan of the diabetes inspection parameters and a management scheme of daily life for the user by combining the evaluation result and the calculation result.
The management system provided by the embodiment aims at providing daily inspection plans and disease management suggestions for users, reducing the risk of illness for the users or guiding the users to cooperate with treatment, paying close attention to prognosis effects, helping the users to monitor and manage diseases themselves, and enabling the disease management of the users to be more planned.
The technical principle of the present invention is described above in connection with the specific embodiments. The description is made for the purpose of illustrating the general principles of the invention and should not be taken in any way as limiting the scope of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of this specification without undue burden.
Claims (2)
1. A diabetes management system, comprising:
the user interaction module is used for receiving corresponding checking parameters according to the working mode selected by the user;
the evaluation module is used for comparing and analyzing the inspection parameters with preset standards to obtain an evaluation result;
the advice output module is used for providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the evaluation result;
the user interaction module is specifically configured to:
If the working mode is risk assessment, the examination parameters are fasting blood glucose value and blood triglyceride value, or sugar load 2h blood glucose value and blood triglyceride value; correspondingly, the evaluation module is specifically configured to: judging the threshold range of the inspection parameter to obtain the risk level of the user suffering from diabetes;
If the working mode is efficacy evaluation, the examination parameters comprise glycosylated hemoglobin value, fasting blood glucose value and blood triglyceride value; correspondingly, the evaluation module is specifically configured to: calculating the variation coefficient of the fasting blood sugar in the period, judging the threshold range of the variation coefficient of the fasting blood sugar and the inspection parameter, or judging the variation condition of the variation coefficient of the fasting blood sugar and the inspection parameter before and after treatment, and obtaining the curative effect grade of executing the treatment scheme by the user;
if the working mode is prognosis evaluation, checking parameters including glycosylated hemoglobin value and/or total cholesterol value; receiving the condition of whether complications exist or not input by a user; correspondingly, the evaluation module is specifically configured to: judging the threshold range of the inspection parameter to obtain the prognosis effect grade of the user; correspondingly, the suggestion output module is specifically configured to: and providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the prognosis effect grade and the condition of the complications.
2. The management system according to claim 1, further comprising: a basic information acquisition module for providing a monitoring plan and a management scheme of the diabetes inspection parameters according to the evaluation result,
Acquiring basic information of a user, including gender, age, height, weight, occupation, daily activity level and diet condition;
correspondingly, the suggestion output module is specifically configured to:
and calculating calories consumed and ingested by the user according to the basic information, and providing a monitoring plan of the diabetes inspection parameters and a management scheme of daily life for the user by combining the evaluation result and the calculation result.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711047697.8A CN110021437B (en) | 2017-10-31 | 2017-10-31 | Diabetes management method and system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711047697.8A CN110021437B (en) | 2017-10-31 | 2017-10-31 | Diabetes management method and system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110021437A CN110021437A (en) | 2019-07-16 |
| CN110021437B true CN110021437B (en) | 2024-04-26 |
Family
ID=67186720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711047697.8A Active CN110021437B (en) | 2017-10-31 | 2017-10-31 | Diabetes management method and system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110021437B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111599473A (en) * | 2020-05-21 | 2020-08-28 | 北京因普乐健康科技有限公司 | Blood glucose related index information processing method and device and electronic equipment |
| CN111710411A (en) * | 2020-05-29 | 2020-09-25 | 中润普达(十堰)大数据中心有限公司 | Intelligent disease presumption system based on blood fat inspection indexes |
| CN111968748A (en) * | 2020-08-21 | 2020-11-20 | 南通大学 | Modeling method of diabetic complication prediction model |
| CN112735588A (en) * | 2021-01-12 | 2021-04-30 | 芜湖云枫信息技术有限公司 | Hierarchical combined management system and method for diabetes and diabetic nephropathy |
| CN116230238B (en) * | 2023-05-08 | 2023-07-21 | 寿光市人民医院 | Monitoring and early warning system for cardiovascular disease |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006011869A2 (en) * | 2004-06-28 | 2006-02-02 | Paul M Rosman | Predictive trement of dysglycemic excursions associated with diabetes mellitus |
| CN102999686A (en) * | 2011-09-19 | 2013-03-27 | 上海煜策信息科技有限公司 | Health management system and implementation method thereof |
| CN103250158A (en) * | 2010-10-15 | 2013-08-14 | 霍夫曼-拉罗奇有限公司 | Medical devices that support enhanced system extensibility for diabetes care |
| WO2014169268A1 (en) * | 2013-04-12 | 2014-10-16 | Biophysical Corporation, Inc. | System and method for identifying patients most likely to subscribe to a prevention program for type-2 diabetes |
| CN104657621A (en) * | 2015-03-09 | 2015-05-27 | 上海万达全程健康门诊部有限公司 | System and method for evaluating body health states based on multi-point collection |
| CN105160199A (en) * | 2015-09-30 | 2015-12-16 | 刘毅 | Continuous blood sugar monitoring based method for processing and displaying diabetes management information with intervention information |
| CN204946110U (en) * | 2015-07-06 | 2016-01-06 | 青岛大学附属医院 | A kind of diabetes electronic records management control system |
| CN105574337A (en) * | 2015-12-16 | 2016-05-11 | 上海亿保健康管理有限公司 | Health evaluation device |
| CN106108857A (en) * | 2016-08-23 | 2016-11-16 | 王伏声 | Diabetic foot classification of severity evaluates system |
| CN106326654A (en) * | 2016-08-24 | 2017-01-11 | 北京辛诺创新科技有限公司 | Big data cloud analysis-based health prediction system, intelligent terminal and server |
| CN106979982A (en) * | 2016-01-19 | 2017-07-25 | 上海市第六人民医院 | It is a kind of to be predicted for diabetes risk, treat the method evaluated and kit |
| CN107016243A (en) * | 2017-04-06 | 2017-08-04 | 浙江大学 | Diabetes risk appraisal procedure |
| CN107292115A (en) * | 2017-07-12 | 2017-10-24 | 冯培根 | Artificial intelligence fititious doctor diagnosis and therapy system and method based on diabetes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1304644A3 (en) * | 2001-09-26 | 2003-09-10 | Siemens Aktiengesellschaft | System for checking of treatment plans |
| US20070167395A1 (en) * | 2006-01-17 | 2007-07-19 | Isaac Eliaz | Compositions and methods for treating diabetes |
| US20100160768A1 (en) * | 2008-12-24 | 2010-06-24 | Marrouche Nassir F | Therapeutic outcome assessment for atrial fibrillation |
| WO2010108092A2 (en) * | 2009-03-19 | 2010-09-23 | Phenotypeit, Inc. | Medical health information system |
| US10390740B2 (en) * | 2010-12-29 | 2019-08-27 | Medtronic Minimed, Inc. | Glycemic health metric determination and application |
| BR112013033254A2 (en) * | 2011-06-23 | 2017-03-01 | Univ Virginia Patent Foundation | system for managing patient glycemic control and computer readable non-transient storage media |
| EP3096253A1 (en) * | 2015-05-19 | 2016-11-23 | Universidad de Vigo | System, computer-implemented method and computer program product for individualized multiple-disease quantitative risk assessment |
-
2017
- 2017-10-31 CN CN201711047697.8A patent/CN110021437B/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006011869A2 (en) * | 2004-06-28 | 2006-02-02 | Paul M Rosman | Predictive trement of dysglycemic excursions associated with diabetes mellitus |
| CN103250158A (en) * | 2010-10-15 | 2013-08-14 | 霍夫曼-拉罗奇有限公司 | Medical devices that support enhanced system extensibility for diabetes care |
| CN102999686A (en) * | 2011-09-19 | 2013-03-27 | 上海煜策信息科技有限公司 | Health management system and implementation method thereof |
| WO2014169268A1 (en) * | 2013-04-12 | 2014-10-16 | Biophysical Corporation, Inc. | System and method for identifying patients most likely to subscribe to a prevention program for type-2 diabetes |
| CN104657621A (en) * | 2015-03-09 | 2015-05-27 | 上海万达全程健康门诊部有限公司 | System and method for evaluating body health states based on multi-point collection |
| CN204946110U (en) * | 2015-07-06 | 2016-01-06 | 青岛大学附属医院 | A kind of diabetes electronic records management control system |
| CN105160199A (en) * | 2015-09-30 | 2015-12-16 | 刘毅 | Continuous blood sugar monitoring based method for processing and displaying diabetes management information with intervention information |
| CN105574337A (en) * | 2015-12-16 | 2016-05-11 | 上海亿保健康管理有限公司 | Health evaluation device |
| CN106979982A (en) * | 2016-01-19 | 2017-07-25 | 上海市第六人民医院 | It is a kind of to be predicted for diabetes risk, treat the method evaluated and kit |
| CN106108857A (en) * | 2016-08-23 | 2016-11-16 | 王伏声 | Diabetic foot classification of severity evaluates system |
| CN106326654A (en) * | 2016-08-24 | 2017-01-11 | 北京辛诺创新科技有限公司 | Big data cloud analysis-based health prediction system, intelligent terminal and server |
| CN107016243A (en) * | 2017-04-06 | 2017-08-04 | 浙江大学 | Diabetes risk appraisal procedure |
| CN107292115A (en) * | 2017-07-12 | 2017-10-24 | 冯培根 | Artificial intelligence fititious doctor diagnosis and therapy system and method based on diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110021437A (en) | 2019-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110021437B (en) | Diabetes management method and system | |
| KR100776070B1 (en) | Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data | |
| CN103889317B (en) | For the unified platform for the blood sugar level that diabetic is monitored and controlled | |
| EP3614394B1 (en) | Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers | |
| US11355238B2 (en) | Method, system and computer program product for evaluation of blood glucose variability in diabetes from self-monitoring data | |
| US7395158B2 (en) | Method of screening for disorders of glucose metabolism | |
| JP4289869B2 (en) | Diabetes diagnosis support system | |
| US20080154513A1 (en) | Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes | |
| Goetsch et al. | The effects of stress, mood, and coping on blood glucose in NIDDM: A prospective pilot evaluation | |
| JP7463590B2 (en) | Methods, devices and systems for physiological parameter analysis - Patents.com | |
| Yogev et al. | Continuous glucose monitoring for treatment adjustment in diabetic pregnancies—a pilot study | |
| AU2001251046A1 (en) | Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data | |
| KR20130135677A (en) | Healthecare method utilizing a self-monitoring of blood sugar date and system thereof | |
| US20210256872A1 (en) | Devices, systems, and methods for predicting blood glucose levels based on a personalized blood glucose regulation model | |
| CN110786865A (en) | System and method for controlling blood glucose using personalized histograms | |
| US20150073754A1 (en) | Method and system for calculating indices for diabetes control | |
| WO2021221591A1 (en) | System and method measuring glucose from urine | |
| Igbe et al. | An absolute magnitude deviation of HRV for the prediction of prediabetes with combined artificial neural network and regression tree methods | |
| US20210158923A1 (en) | Distributed user monitoring system | |
| US20100106000A1 (en) | Methods and Systems for Evaluating Glycemic Control | |
| KR102326690B1 (en) | Blood glucose management method using non-invasive device | |
| US20210177313A1 (en) | Continuous health monitoring system | |
| US20230270362A1 (en) | Continuous health monitoring system | |
| CN117894424B (en) | Recommendation system for constructing T2DM patient drug scheme based on deep learning and reinforcement learning | |
| López Ruiz et al. | IoT-driven Real-Time Glucose Monitoring: Empowering Diabetes Care and Prevention |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |